Publicacións nas que colabora con Soledad López Calvo (20)

2023

  1. Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort

    European Journal of Hospital Pharmacy, Vol. 30, Núm. 4, pp. 221-226

2022

  1. Discontinuation due to neuropsychiatric adverse events with efavirenz-and dolutegravir-based antiretroviral therapy: a comparative real-life study

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 207-211

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

2019

  1. Teleconsultation for the Pharmaceutical Care of HIV Outpatients in Receipt of Home Antiretrovirals Delivery: Clinical, Economic, and Patient-Perceived Quality Analysis

    Telemedicine and e-Health, Vol. 25, Núm. 5, pp. 399-406

  2. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

    Basic and Clinical Pharmacology and Toxicology, Vol. 124, Núm. 4, pp. 479-490

2014

  1. High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response

    AIDS, Vol. 28, Núm. 12, pp. 1837-1840

2010

  1. Peginterferón alfa-2b y Ribavirina en pacientes coinfectados VIH-VHC: eficacia y seguridad en la práctica clínica habitual

    Galicia Clínica, Vol. 71, Núm. 4, pp. 161-168

2006

  1. "Liver toxicity and metabolic alterations associated with nevirapine therapy and the influence of hepatitis C virus infection"

    Nutrition and Metabolic Disorders in HIV Infection, Vol. 5, Núm. 1, pp. 891-897

  2. Hepatitis víricas en usuarios de drogas

    Adicciones: Revista de socidrogalcohol, Vol. 18, Núm. 1, pp. 115-136

2005

  1. 67 year old male, chronic alcholism and hydropic descompensation

    Revista Clinica Espanola

2004

  1. Total HCV core antigen assay: A new marker of HCV viremia and its application during treatment of chronic hepatitis C

    Journal of Virological Methods, Vol. 120, Núm. 2, pp. 173-177

2003

  1. Virus GB-C: ausencia de asociación con niveles de transaminasas, CD4 y carga vírica en pacientes con sida

    Anales de medicina interna, Vol. 20, Núm. 4, pp. 175-178

2002

  1. Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations

    Medical Science Monitor, Vol. 8, Núm. 9

  2. Telogen effluvium as a clinical presentation of human immunodeficiency virus infection [6]

    American Journal of Medicine

2001

  1. Eficacia del TAC abdominal en el diagnóstico de la acumulación de grasa víscero-abdominal en pacientes con infección por VIH tratados con inhibidores de proteasas

    Anales de medicina interna, Vol. 18, Núm. 8, pp. 452-453

  2. Eficacia del TAC abdominal en el diagnóstico de la acumulación de grasa víscero-abdominal en pacientes con infección por VIH tratados con inhibidores de proteasas.

    Anales de Medicina Interna

1999

  1. Long-term re-treatment with interferon and ribavirin combination therapy in patients with chronic hepatitis C who are non-responders to interferon alone: A preliminary study

    Scandinavian Journal of Infectious Diseases, Vol. 31, Núm. 4, pp. 359-361

  2. Tuberculosis, SIDA y terapia antirretrovírica.

    Revista Clinica Espanola

1997

  1. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients

    Journal of Infection, Vol. 35, Núm. 3, pp. 225-230

1994

  1. Síndrome De Inmunodeficiencia Adquirida (SIDA) en el área sanitaria de La Coruña (1984-1994). Estudio epidemiológico

    Galicia Clínica, Vol. 66, Núm. 1, pp. 11-143143